Executive Summary
TAVR now matches surgical bioprosthesis durability at 7 years in newly reported registry-level follow-up (via Medscape), arriving the same day TRiCares dosed the first patient in the TRICURE US IDE head-to-head against Edwards' EVOQUE — the first randomized-style comparison of two TTVR platforms. A parallel STS/ACC TVT Registry analysis in JACC Advances dismantles the "obesity paradox" in TAVR by age, showing lower BMI is a high-risk phenotype only in patients ≥75. Combined, today tightens the case for TAVR in older patients where durability was the last surgical redoubt, while opening a genuine competitive market in tricuspid replacement — but leaves the sub-70 durability question, and the ESC 2025 vs ACC/AHA 2020 age-threshold gap, unresolved.
- 7-year TAVR-vs-SAVR durability parity narrows the surgical durability argument that has anchored ACC/AHA's <65 SAVR preference (Medscape).
- Among 6,639 TAVR patients, BMI <25 kg/m² carried a 29% higher 1-year mortality risk in those ≥65 (aHR 1.29) and a 64% higher risk in those ≥85 (aHR 0.36 for high BMI) (JACC Advances).
- TRiCares launched TRICURE, the first randomized IDE head-to-head between Topaz and Edwards EVOQUE for severe TR (Cardiovascular Business).
- Adding RV-PA coupling (TAPSE/PASP <0.44) to the TRI-SCORE improved C-index from 0.614 to 0.710 in isolated TR, sharpening timing of intervention (Open Heart).
- CT-FFR ≤0.80 pre-AVR independently predicted MACE (HR 4.84) across both TAVR and SAVR cohorts, outperforming anatomical CCTA alone (BMC Medical Imaging).
What to watch: Edwards reports Q2 earnings July 23 — first read on whether TAVR volumes and the newly contested TTVR franchise are absorbing the durability-parity narrative.
Aortic Valve (TAVR/TAVI)
The 7-year durability parity report is the day's most consequential aortic finding, and it lands squarely on the ACC/AHA vs ESC age-threshold disagreement. Medscape's reporting of the 7-year data extends the durability window that ESC 2025 already accepted when it lowered the TAVI-preferred floor to age 70. The ACC/AHA 2020 <65 SAVR preference was built on the assumption robust TAVR durability extended only to ~5 years; that assumption is now weaker. Surgical counterpoint: current ACC/AHA guidelines still recommend SAVR (Class I) below age 65, and both guidelines agree SAVR remains preferred for bicuspid disease, small annuli requiring enlargement, and concomitant aortopathy — none of which today's durability data addresses. Separately, the STS/ACC TVT Registry obesity paradox analysis (N=6,639, retrospective, industry-adjacent) clarifies that lower BMI in older TAVR patients is a frailty marker, not a protective phenotype — the effect strengthens with age (aHR 0.36 for BMI ≥25 in patients ≥85). A CT-FFR prognostic study (N=329, single-center, 17-month follow-up) shows CT-FFR ≤0.80 predicts MACE (HR 4.84) after both TAVR and SAVR, adding functional coronary assessment to pre-AVR workup.
Mitral Valve (MitraClip, PASCAL, TMVR)
No pivotal mitral trial today, but a case series worth noting on the edges of guideline territory. A DragonFly TEER case in a 90-year-old with mixed degenerative and atrial functional MR and a small MVA (4.09 cm²) illustrates the anatomical ceiling for multi-clip TEER — precisely the scenario the ESC 2025 atrial secondary MR pathway now formally recognizes. Surgical counterpoint: ESC 2025 lists MV surgery + surgical AF ablation + LAAO as Class IIa for atrial SMR, with TEER (Class IIb) reserved for inoperable patients. A hybrid TEER-plus-vascular-plug case for commissural DMR points to the anatomical limits of edge-to-edge repair where ACC/AHA and ESC both favor surgical repair (Class I) in operable patients. A TMVR valve-in-valve rescue under Impella support for cardiogenic shock from bioprosthetic leaflet tear extends the emerging use case for percutaneous mitral reintervention. Notable absence today: no ESC-relevant COAPT-adjacent data, which remains the practice-changing wedge between the guidelines (Class I in ESC 2025, Class IIa in ACC/AHA 2020).
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] The TRICURE US IDE launch is the first randomized comparison between two dedicated TTVR platforms — TRiCares Topaz versus Edwards EVOQUE. This is the first real device competition in a category ESC 2025 elevated to Class IIa (LOE A) for high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary PH. ACC/AHA 2020 didn't address transcatheter TR therapy at all. Surgical counterpoint: ESC 2025 upgraded TV surgery for symptomatic severe primary TR to Class I; TTVR remains reserved for prohibitive surgical risk. Today's tricuspid case literature is uneasy reading. Reports include valve-in-valve for early Topaz TTVR leaflet dysfunction at 6 months, acute EVOQUE leaflet thrombosis with PFO-mediated hypoxemia, and the first documented fatal prosthetic valve endocarditis after TTVR. Early-device durability and antithrombotic regimens after TTVR are unresolved. The TAPSE/PASP + TRI-SCORE analysis (N=93, retrospective) advances the "before the window closes" question of timing — a persistent theme in ESC 2025's stepwise TR framework.
Surgical vs. Transcatheter Comparisons
No dedicated head-to-head today, but the 7-year TAVR durability report sits directly against SAVR's historical durability claim. The CT-FFR analysis is one of the few pre-AVR studies to enroll both TAVR and SAVR patients (N=329) and demonstrated consistent prognostic value across both — a rare methodological example of not choosing sides. A separate analysis reinforces that pre-AVR coronary functional assessment matters regardless of the eventual valve strategy. The frailty commentary in Cardiovascular Revascularization Medicine reinforces that clinical judgment and formal frailty scores are complementary in TAVR patient selection — which is exactly the Heart Team framework both guidelines endorse but rarely operationalize consistently.
Device & Technology
A German registry (N=32) of fully percutaneous transaxillary TAVI using off-label MANTA or double-ProGlide closure reported a 25% VCD failure rate and 12.5% covered-stent bailout — a reminder that alternative access remains skill-dependent. A delayed chimney stent fracture case one month post-TAVR highlights an underappreciated late complication of coronary protection in self-expanding valve frames. The first report of a premounted dry valve system used in a tortuous descending aorta speaks to durability-focused device evolution in China, where the value proposition targets younger patients — precisely the population ESC 2025 still recommends for SAVR. A hybrid biofabrication platform for patient-specific aortic phantoms and a 3D-printed model-guided simultaneous TAVR and TMVR-in-MAC point to the growing role of pre-procedural simulation in complex anatomy.
Regulatory & Policy
No new FDA or CMS actions today. TRiCares' IDE launch is regulatory-adjacent — the study design will define the pivotal endpoints on which second-generation TTVR devices are judged and reimbursed.
Industry & Market
Ascension St. Vincent Evansville marked its 1,000th TAVR — a data point for the community-hospital penetration of TAVR that continues to outpace the pace at which SAVR volumes have declined. A separate report on cost-effective cardiac surgery in Africa (referenced in our editorial knowledge base via the 2025 Accra Declaration) is a reminder that TAVR-versus-SAVR debates in wealthy markets ignore that most of the world lacks reliable access to either.
Financial Analysis
Edwards Lifesciences ended the session down 2.47% at $91.33, underperforming peers for the second consecutive day per MarketWatch. The clinical context: today's TRICURE IDE announcement introduces the first real competitor to EVOQUE in a franchise Edwards has essentially owned since FDA approval in 2024. Combined with the 7-year TAVR durability data supporting TAVR volume growth, the market is repricing Edwards on TTVR risk rather than SAPIEN strength. Anteris (AVR.AX) sits up 91% over six months on its DurAVR clinical progression, though its analyst coverage remains a single sell-side voice. Boston Scientific's 53% six-month decline is unrelated to structural heart specifically but weighs on comparative valuation across the peer set.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $91.33, -2.47% on the day; +10.02% over 6 months; 52-week range $72.30–$96.29.
- Market cap $52.6B; trailing P/E 50.46; forward P/E 27.12; beta 0.85.
- Analyst consensus: buy, target $97.92 (range $84–$110, 26 analysts).
- Next earnings July 23; consensus EPS $0.74, revenue $1.70B.
- Two-day underperformance coincides with TRICURE IDE announcement — first direct EVOQUE competition. Q2 print will be the first chance to see whether TTVR share erosion is priced in or emerging.
Medtronic (MDT)
- Close $82.39, +0.46%; -13.55% over 6 months; 52-week range $73.31–$106.33.
- Market cap $105.5B; trailing P/E 21.97; forward P/E 12.86; beta 0.58.
- Analyst consensus: buy, target $97.73 (range $78–$121, 26 analysts).
- Next earnings August 18; consensus EPS $1.39, revenue $9.55B.
- Evolut low-risk 10-year durability data will matter more to MDT than any single quarter; today's 7-year parity narrative helps the TAVR franchise generally but doesn't differentiate.
Abbott (ABT)
- Close $94.40, -0.82%; -23.40% over 6 months; 52-week range $81.97–$137.49.
- Market cap $164.4B; trailing P/E 26.44; forward P/E 15.59; beta 0.61.
- Analyst consensus: buy, target $116.40 (range $92–$135, 25 analysts).
- Next earnings July 16; consensus EPS $1.28, revenue $12.52B.
- Navitor and TriClip both featured in today's case literature; the structural heart segment is a small share of ABT revenue, but the six-month decline reflects broader diagnostics and nutrition pressure, not valve-specific weakness.
Boston Scientific (BSX)
- Close $44.99, +0.40%; -53.00% over 6 months; 52-week range $42.25–$109.50.
- Market cap $66.9B; trailing P/E 18.75; forward P/E 12.12; beta 0.58.
- Analyst consensus: strong buy, target $73.86 (range $55–$106, 29 analysts).
- Next earnings July 29; consensus EPS $0.83, revenue $5.37B.
- The Sentinel cerebral embolic protection franchise remains BSX's most direct structural heart exposure. Consensus target implies 64% upside — the widest gap in our coverage universe.
Anteris Technologies (AVR.AX)
- Close A$13.34, -2.06%; +91.39% over 6 months; 52-week range A$4.68–$15.47.
- Market cap A$1.3B; forward P/E negative (pre-commercial); beta 0.73.
- Analyst coverage thin: 1 analyst, target A$13.00.
- DurAVR next-generation biomimetic TAVR platform driving the six-month rally; near-term catalysts are pivotal enrollment progression and durability readouts.
Market outlook: The structural heart trade is bifurcating. Established TAVR names (EW, MDT) are being repriced on incremental durability confirmation and expansion into TR — where competition is now real. Pre-commercial names (AVR.AX) trade on catalyst calendars. The 7-year durability report is a rising-tide event for the incumbents; the TRICURE IDE launch is a franchise-specific risk event for Edwards. Watch July 16 (ABT) through July 29 (BSX) for how much of this narrative is already in the numbers. Private players — JenaValve, Meril, J Valve — remain the wild card, particularly as premounted dry-valve platforms move into complex anatomy.
Clinical Trial Updates
TRICURE US IDE (TRiCares Topaz vs Edwards EVOQUE) opened enrollment with the first patient treated at Piedmont Healthcare by Pradeep Yadav, per Cardiovascular Business and The Manila Times. The design targets severe or greater TR with the femoral vein primary access.
Preprint Highlights
No structural heart-relevant preprints on bioRxiv/medRxiv today. The two preprints in the feed cover pediatric vaccine immunology and corneal neurotrophic keratopathy — outside our coverage.
Coming up: Abbott reports July 16 (first structural heart read of Q2 earnings season), Edwards on July 23. Watch for TTVR volume commentary and any updated guidance on how Edwards models EVOQUE against a competitive IDE. Beyond earnings, the next data-driven inflection points are longer-term Evolut Low Risk follow-up and readouts on how ESC 2025's early-intervention pathway for asymptomatic severe AS is changing referral patterns in Europe.